# Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)

> **NCT07714213** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Christiana Franke** · enrollment: 138 (estimated)

## Conditions studied

- Post-acute Infectious Syndrome (PAIS)
- Post-COVID-19 Condition (PCC or Long COVID)

## Interventions

- **DRUG:** Aripiprazole (low-dose, 1mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07714213
- **Lead sponsor:** Christiana Franke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-05-15
- **Final completion:** 2028-12-31
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714213, "Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*